RSA makes three appointments
pharmafile | October 9, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Mateja Forstnaric, Nicholas Draeger, Stefanie Blasi, rsa
Life sciences executive search and interim management firm RSA has appointed three consultants to its European teams.
Stefanie Blasi (pictured) will join the firm as an associate consultant in its Interims unit. She already has experience in recruiting interim managers in the industry gained through a major recruitment business previously in Frankfurt.
Bringing knowledge of quality management, regulatory affairs and sales and marketing roles, Blasi will work with RSA interim divisions in Germany, Switzerland and Austria.
Mateja Forstnaric joins RSA as a director for Central Europe. She brings with her over 20 years of executive search and consulting experience in Austria, and Central and Eastern Europe.
Prior to joining RSA, Mateja worked at a variety of consulting firms including Odgers Berndtson and Heidrick & Struggles, where she was a partner.
Dr Nicholas Draeger joins RSA as a senior consultant. He takes with him over 20 years of experience in healthcare including working for big pharma, biotech and medical devices in research, business development and fund management capacities.
He previously worked with Roche and Recordati, before heading the biotech sales-side research group at the French finance group, Credit Agricole Indosuez Cheuvreux.
“We have, for this year, over-achieved budget, and are proving profitable. That’s why we have the power to invest in new hires, and that’s why we’re also looking for more people in addition to those we have already recruited,” says Kristian Juergensen, head of DACH and managing director, RSA Germany.
Related Content
Hold your horses: M&A is about talent, not just pipelines
The morning mist is rising on the battlefield. At stake: the crown riches and glory …
Addressing the boardroom gender gap
The issue of gender balance within UK boards has moved quickly up the business agenda …
UK pharma downbeat on its future – survey
The impacts of NHS reform and the increasingly high cost of R&D is causing pharma …
